A detailed history of Lmr Partners LLP transactions in Legend Biotech Corp stock. As of the latest transaction made, Lmr Partners LLP holds 124,400 shares of LEGN stock, worth $4.99 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
124,400
Previous 127,000 2.05%
Holding current value
$4.99 Million
Previous $5.62 Million 7.79%
% of portfolio
0.06%
Previous 0.06%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$43.55 - $59.88 $113,229 - $155,688
-2,600 Reduced 2.05%
124,400 $6.06 Million
Q2 2024

Aug 14, 2024

BUY
$39.5 - $57.22 $991,450 - $1.44 Million
25,100 Added 24.63%
127,000 $5.62 Million
Q1 2024

May 15, 2024

BUY
$55.06 - $69.99 $836,912 - $1.06 Million
15,200 Added 17.53%
101,900 $5.72 Million
Q4 2023

Feb 14, 2024

BUY
$57.25 - $69.74 $675,378 - $822,722
11,797 Added 15.75%
86,700 $5.22 Million
Q3 2023

Nov 14, 2023

BUY
$63.16 - $76.5 $170,721 - $206,779
2,703 Added 3.74%
74,903 $5.03 Million
Q2 2023

Aug 14, 2023

SELL
$46.28 - $75.01 $860,808 - $1.4 Million
-18,600 Reduced 20.48%
72,200 $4.98 Million
Q1 2023

May 15, 2023

BUY
$43.42 - $57.37 $846,690 - $1.12 Million
19,500 Added 27.35%
90,800 $4.38 Million
Q4 2022

Feb 14, 2023

BUY
$38.8 - $55.46 $582,000 - $831,900
15,000 Added 26.64%
71,300 $3.56 Million
Q2 2022

Aug 15, 2022

BUY
$33.54 - $55.0 $1.1 Million - $1.8 Million
32,749 Added 139.06%
56,300 $3.1 Million
Q1 2022

May 16, 2022

BUY
$31.02 - $48.18 $404,811 - $628,749
13,050 Added 124.27%
23,551 $856,000
Q4 2021

Feb 14, 2022

BUY
$41.14 - $56.98 $432,011 - $598,346
10,501 New
10,501 $489,000

Others Institutions Holding LEGN

About Legend Biotech Corp


  • Ticker LEGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 167,403,008
  • Market Cap $6.72B
  • Description
  • Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...
More about LEGN
Track This Portfolio

Track Lmr Partners LLP Portfolio

Follow Lmr Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lmr Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Lmr Partners LLP with notifications on news.